ABCC8在胶质瘤中的表达及其临床意义  

Expression of ATP binding cassette subfamily C member 8 and its clinical significance in gliomas

作　　者：周开甲[1] 刘彦伟[2] 赵征 张鸣[1] 刘伯伟[1] Zhou Kaijia;Liu Yanwei;Zhao Zheng;Zhang Ming;Liu Bowei(Department of Neuro-Oncology Surgery,Fujian Cancer Hospital&Cancer Hospital Affiliated to Fujian Medical University,Fuzhou 350014,China;Department of Neurosurgery,Beijing Tiantan Hospital Affiliated to Capital Medical University,Beijing Neurosurgical Institute,Beijing 100070,China)

机构地区：[1]福建省肿瘤医院福建医科大学附属肿瘤医院神经肿瘤外科,福州350014 [2]首都医科大学附属北京天坛医院神经外科北京神经外科研究所,100070

出　　处：《中华神经医学杂志》2020年第12期1260-1266,共7页Chinese Journal of Neuromedicine

摘　　要：目的探讨ATP结合盒亚家族C成员8(ABCC8)在不同类型胶质瘤中的表达情况及其与患者总生存期的关系。方法收集中国胶质瘤基因组图谱(CGGA)数据库中516例胶质瘤患者的ABCC8 mRNA数据及患者相应的临床特征[性别、年龄、组织病理类型、WHO分级、异柠檬酸脱氢酶(IDH)突变状态、1p/19q缺失状态及分子病理分型]、总生存期等,比较不同类型胶质瘤患者间ABCC8 mRNA的表达差异,以及不同类型胶质瘤患者中ABCC8 mRNA高表达(≥54.50)与ABCC8 mRNA低表达(<54.50)患者间总生存期的差异。结果(1)原发性胶质瘤患者的ABCC8 mRNA表达明显高于复发性患者,差异有统计学意义(P<0.05)。少枝胶质细胞瘤患者的ABCC8 mRNA表达最高,星形胶质细胞瘤患者次之,胶质母细胞瘤患者最低,不同组织病理类型胶质瘤患者间差异均有统计学意义(P<0.05)。WHOⅡ级胶质瘤患者的ABCC8 mRNA表达最高,WHOⅢ级患者次之,WHOⅣ级患者最低,不同WHO分级患者间差异均有统计学意义(P<0.05)。IDH突变型胶质瘤患者的ABCC8 mRNA表达明显高于IDH野生型患者,1p/19q缺失胶质瘤患者的ABCC8 mRNA表达明显高于1p/19q不缺失患者,差异均有统计学意义(P<0.05)。低级别胶质瘤患者及胶质瘤母细胞瘤患者中IDH突变型患者的ABCC8 mRNA表达均明显高于IDH野生型患者,差异均有统计学意义(P<0.05)。(2)在所有胶质瘤患者以及原发性、复发性胶质瘤,少枝胶质细胞瘤、星形胶质细胞瘤,WHO低级别(Ⅱ级)、WHO高级别(Ⅲ、Ⅳ级)胶质瘤,IDH突变型、IDH野生型胶质瘤,1p/19q缺失、1p/19q无缺失胶质瘤患者中,ABCC8 mRNA高表达患者的总生存期均明显长于ABCC8 mRNA低表达患者,差异均有统计学意义(P<0.05)。(3)多因素Cox回归分析显示ABCC8 mRNA表达是胶质瘤患者总生存期的独立影响因素(HR=0.747,P=0.025,95%CI:0.579~0.963)。结论胶质瘤患者中ABCC8 mRNA的表达与肿瘤恶性程度有关,且其可以作为预测患者预Objective To analyze the expression of ATP binding cassette subfamily C member 8(ABCC8)in different types of gliomas and its relation with overall survival of glioma patients.Methods The ABCC8 mRNA data and clinical data(gender,age,histopathology,WHO grading,isocitrate dehydrogenase[IDH]mutation status,1p/19q deletion status and molecular types),and overall survival of 516 glioma patients from the Cancer Genome Atlas were collected,and the differences of ABCC8 mRNA expression in different types of glioma patients were compared.The differences of overall survival were compared between high(≥54.50)and low(<54.50)ABCC8 mRNA expression patients in different types of glioma patients.Results(1)ABCC8 mRNA expression in primary glioma patients was significantly higher than that in recurrent glioma patients(P<0.05).ABCC8 mRNA expression was the highest in oligodendroglioma patients,followed by astrocytoma patients;and glioblastoma patients had the lowest ABCC8 mRNA expression;the differences among glioma patients from subgroups of different histopathological types were statistically significant(P<0.05).ABCC8 mRNA expression was the highest in patients with grade II glioma,followed by those with grade III(P<0.05);and patients with grade IV had the lowest ABCC8 mRNA expression(P<0.05);the differences among patients from subgroups of different WHO grading were statistically significant(P<0.05).ABCC8 mRNA expression in glioma patients with IDH mutant was significantly higher than that in glioma patients with IDH wild-type(P<0.05);and ABCC8 mRNA expression in patients with 1P/19Q deletion glioma was significantly higher than that in patients with 1P/19Q deletion(P<0.05).ABCC8 mRNA expression in low-grade glioma patients and glioblastoma multiforme patients with IDH mutation was significantly higher than that in patients with IDH wild-type(P<0.05).(2)In all patients with glioma,primary and recurrent glioma,oligodendroglioma,neuroastrocytoma,WHO low-grading(grade II)and WHO high-grading(grade III or IV)glioma,IDH mutation and

关 键 词：神经胶质瘤 ATP结合盒亚家族C成员8 预后评估 

分 类 号：R739.41[医药卫生—肿瘤]